Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Taro Pharm Inds (TARO) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 4,368,980
  • Shares Outstanding, K 42,770
  • Annual Sales, $ 950,750 K
  • Annual Income, $ 540,930 K
  • 36-Month Beta 0.81
  • Price/Sales 4.51
  • Price/Book 2.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.28 +12.46%
on 11/03/16
115.91 -10.47%
on 11/09/16
+2.73 (+2.70%)
since 11/02/16
3-Month
92.28 +12.46%
on 11/03/16
127.57 -18.65%
on 09/06/16
-22.59 (-17.88%)
since 09/02/16
52-Week
92.28 +12.46%
on 11/03/16
157.99 -34.31%
on 12/28/15
-36.56 (-26.05%)
since 12/02/15

Most Recent Stories

More News
TARO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Taro Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries...

Taro Announces Appointment of Interim CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that its Board of Directors has appointed Mr. Abhay Gandhi to the position of Interim Chief Executive...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 27, 2016

The following statement is being issued by Levi & Korsinsky, LLP:

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Taro Pharmaceutical Industries Ltd. (TARO) and Lead Plaintiff Deadline December 26, 2016

NEW YORK, NY / ACCESSWIRE / November 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or the...

TARO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Taro Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Taro Pharmaceutical Industries Ltd. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 22, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Taro Pharmaceutical Industries ("Taro" or the "Company") (NYSE: TARO)...

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed Against Taro Pharmaceutical Industries Ltd.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") on...

Taro Announces Appointment of New CEO and New Board Member Nominations

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today the appointment of Mr. Uday Baldota as Chief Executive Officer and as a nominee to Taro's Board...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Taro Pharmaceutical Industries Ltd To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit - TARO

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

TARO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Taro Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Support & Resistance

2nd Resistance Point 106.63
1st Resistance Point 105.20
Last Price 103.78
1st Support Level 101.01
2nd Support Level 98.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.